| human | Q5 |
| P496 | ORCID iD | 0000-0003-4442-7412 |
| P108 | employer | National Institute of Mental Health | Q1967405 |
| P734 | family name | Zarate | Q37262201 |
| Zarate | Q37262201 | ||
| Zarate | Q37262201 | ||
| P735 | given name | Carlos | Q364753 |
| Carlos | Q364753 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q92339977 | (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions |
| Q38379042 | A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression |
| Q39961519 | Aberrant intrinsic functional connectivity within and between corticostriatal and temporal-parietal networks in adults and youth with bipolar disorder. |
| Q38758007 | Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder |
| Q121721324 | Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data |
| Q91843765 | Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function |
| Q58558017 | Are 24-hour motor activity patterns associated with continued rapid response to ketamine? |
| Q60492108 | Characterizing the course of suicidal ideation response to ketamine |
| Q53076446 | Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. |
| Q91614908 | Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression |
| Q92575909 | Correction to: Mapping anticipatory anhedonia: an fMRI study |
| Q64065819 | Correction: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression |
| Q91379850 | Depression in the Primary Care Setting |
| Q92541885 | Depression in the Primary Care Setting. Reply |
| Q89709959 | Development of the Ketamine Side Effect Tool (KSET) |
| Q57482371 | Disentangling the association of depression on the anti-fatigue effects of ketamine |
| Q92073481 | Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants |
| Q92772870 | Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation |
| Q93033299 | Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment |
| Q60044810 | Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression |
| Q92649441 | Familial Aggregation and Coaggregation of Suicide Attempts and Comorbid Mental Disorders in Adults |
| Q91564419 | Functional Imaging of the Implicit Association of the Self With Life and Death |
| Q49712849 | Glutamatergic Modulators in Depression. |
| Q93177074 | Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments |
| Q91087662 | Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant |
| Q37268300 | Increased rate of non-right-handedness in patients with bipolar disorder |
| Q55438088 | Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. |
| Q92898303 | Ketamine for Treatment-Resistant Mood Disorders |
| Q51766804 | Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. |
| Q64977274 | Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. |
| Q36919594 | Ketamine regulates the presynaptic release machinery in the hippocampus |
| Q47615913 | Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood. |
| Q94658369 | Ketamine: a new chapter in antidepressant development |
| Q92586258 | Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression |
| Q91571986 | Mapping anticipatory anhedonia: an fMRI study |
| Q57293270 | Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants |
| Q92622786 | Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder |
| Q91489695 | Neurobiological research with suicidal participants: A framework for investigators |
| Q91298328 | Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder |
| Q44013092 | Olanzapine versus divalproex in the treatment of acute mania |
| Q44495168 | Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study |
| Q60492109 | PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects |
| Q49967356 | Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales |
| Q58772220 | Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects |
| Q64082982 | Prognosis and improved outcomes in major depression: a review |
| Q89472041 | RETRACTED: F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen With the Antidepressant Response of Ketamine |
| Q92887476 | Rapid effects of S-ketamine on the morphology of hippocampal astrocytes and BDNF serum levels in a sex-dependent manner |
| Q91058902 | Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues |
| Q31057535 | Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health |
| Q37424333 | Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories |
| Q91320586 | Symptom trajectories in the months before and after a suicide attempt in individuals with bipolar disorder: A STEP-BD study |
| Q90506196 | Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study |
| Q47402907 | The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. |
| Q30583384 | The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders |
| Q47595593 | The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. |
| Q92418800 | The influence of ketamine on drug discovery in depression |
| Q91303004 | The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response |
| Q42640394 | What Should be Done When Elderly Patients with Major Depression Have Failed to Respond to All Treatments? |
| Q92189038 | What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium |
| Q98161313 | What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA Bipolar Disorder Working Group |
Search more.